| Scorecard |
|---|
|
2 / 5 Stars
|
|
Lipper
2
2
5
2
3
|
|
Zacks Investment Research
3
(Hold)
|
|
Standard & Poor's
2 / 5 Stars
|
|
TheStreet.com
B+
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Net | |
|---|---|---|
| Cash | 0.36 | 0.36 |
| Stocks | 79.12 | 79.12 |
| Bonds | 0.0 | 0.0 |
| Other | 0.49 | 0.49 |
| Foreign Bonds | 0.0 | 0.0 |
| Foreign Stocks | 20.03 | 20.03 |
| Convertible | 0.0 | 0.0 |
| Preferred | 0.0 | 0.0 |
Updated 04.30.2013
Top 10 Holdings
Performance as of 05.31.2013
Portfolio as of 04.30.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Pfizer Inc | PFE | 12.56 | 5.64 |
| Gilead Sciences Inc | GILD | 44.64 | 5.29 |
| Vertex Pharmaceuticals | VRTX | 89.33 | 4.97 |
| Merck & Co Inc | MRK | 19.39 | 4.27 |
| Allergan, Inc. | AGN | 7.97 | 3.95 |
| Johnson & Johnson | JNJ | 22.65 | 3.01 |
| Sanofi | SAN | --- | 2.87 |
| Alexion Pharmaceuticals, Inc. | ALXN | 1.86 | 2.79 |
| Novo Nordisk A/S | NONOF | 1.46 | 2.67 |
| Roche Holding AG | RHHVF | 21.67 | 2.58 |
